The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Cytochrome P450 pharmacogenetics and cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
The Aryl Hydrocarbon Receptor Complex
Hankinson, O. (1995) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.35.040195.001515 · Cited by 1,649 · cited 1×
“Cancer incidence, cancer therapy and CYP polymorphisms CYP1A1/2 CYP1A1 is expressed extrahepatically and CYP1A2 is mainly expressed in the liver, indicating a very different basal regulation, but they share induction via the aryl hydrocarbon receptor (AhR), similarly to CYP1B1 (Hankinson, 1995).”
BackgroundNebert, D. W., Dalton, T. P., Okey, A. B., & Gonzalez, F. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r400004200 · Cited by 1,182
Ingelman-Sundberg, M. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500285 · Cited by 1,108
Self-citationNelson, D. R., Zeldin, D. C., Hoffman, S. M., Maltais, L. J., Wain, H. M., & Nebert, D. W. (2004) · Pharmacogenetics · doi:10.1097/00008571-200401000-00001 · Cited by 1,027
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751
Ingelman-Sundberg, M. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.02.007 · Cited by 676
Self-citationHayashi, S.-I., Watanabe, J., & Kawajiri, K. (1991) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a123619 · Cited by 666
Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M. L., Sjöqvist, F., & Ingelman-Sundberg, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11825 · Cited by 644
Self-citationLang, T., Klein, K., Fischer, J., Nussler, A. K., Neuhaus, P., Hofmann, U., Eichelbaum, M., Schwab, M. G., & Zanger, U. M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200107000-00004 · Cited by 574
Lacroix, D., Sonnier, M., Moncion, A., Cheron, G., & Cresteil, T. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00625.x · Cited by 539
A MONOHYDROXYLATED METABOLITE OF TAMOXIFEN WITH POTENT ANTIOESTROGENIC ACTIVITY
JORDAN, V. C., COLLINS, M. M., ROWSBY, L., & PRESTWICH, G. (1977) · Journal of Endocrinology · doi:10.1677/joe.0.0750305 · Cited by 506
Enzyme-Catalyzed Activation of Anticancer Prodrugs
Rooseboom, M., Commandeur, J. N. M., & Vermeulen, N. P. E. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.1.3 · Cited by 497
Dai, D., Zeldin, D. C., Blaisdell, J. A., Chanas, B., Coulter, S. J., Ghanayem, B. I., & Goldstein, J. A. (2001) · Pharmacogenetics · doi:10.1097/00008571-200110000-00006 · Cited by 494
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling
Clarke, R., Liu, M. C., Bouker, K. B., Gu, Z., Lee, R. Y., Zhu, Y., Skaar, T. C., Gomez, B., O'Brien, K., Wang, Y., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206937 · Cited by 478
Clinical consequences of cytochrome P450 2C9 polymorphisms
KIRCHHEINER, J., & BROCKMOLLER, J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.08.009 · Cited by 474
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
Williams, J. A., Ring, B. J., Cantrell, V. E., Jones, D. R., Eckstein, J., Ruterbories, K., Hamman, M. A., Hall, S. D., & Wrighton, S. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.8.883 · Cited by 471
Effects of St. John's wort on irinotecan metabolism.
Mathijssen, R. H. J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.16.1247 · Cited by 457
Özdemir, V., KALOW, W., Tang, B.-K., Paterson, A. D., Walker, S. E., Endrényi, L., & Kashuba, A. D. M. (2000) · Pharmacogenetics · doi:10.1097/00008571-200007000-00001 · Cited by 440
Buters, J. T. M., Sakai, S., Richter, T., Pineau, T., Alexander, D. L., Savas, U., Doehmer, J., Ward, J. M., Jefcoate, C. R., & Gonzalez, F. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.1977 · Cited by 383
Potter, G. A., Patterson, L. H., Wanogho, E., Perry, P. J., Butler, P. C., Ijaz, T., Ruparelia, K. C., Lamb, J. H., Farmer, P. B., Stanley, L. A., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600197 · Cited by 380
Regulation of the Human CYP2B6 Gene by the Nuclear Pregnane X Receptor
Goodwin, B., Moore, L. B., Stoltz, C. M., McKee, D. D., & Kliewer, S. A. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12603-x · Cited by 374
Substrates of human hepatic cytochrome P450 3A4
Li, A. (1995) · Toxicology · doi:10.1016/0300-483x(95)03155-9 · Cited by 367
Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4
Rebbeck, T. R., Jaffe, J. M., Walker, A. H., Wein, A. J., & Malkowicz, S. B. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.16.1225 · Cited by 360
Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma
Friedman, H. S., Petros, W. P., Friedman, A. H., Schaaf, L. J., Kerby, T., Lawyer, J., Parry, M., Houghton, P. J., Lovell, S., Rasheed, K., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1516 · Cited by 357
Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms
Ingelman-Sundberg, M. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0819-z · Cited by 353
Self-citationCytochrome P450 Gene Polymorphism and Cancer
Agundez, J. (2004) · Current Drug Metabolism · doi:10.2174/1389200043335621 · Cited by 292
Jiang, J.-G., Chen, C.-L., Card, J. W., Yang, S., Chen, J.-X., Fu, X.-N., Ning, Y.-G., Xiao, X., Zeldin, D. C., & Wang, D. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4173 · Cited by 284
Goh, B.-C., Lee, S.-C., Wang, L.-Z., Fan, L., Guo, J.-Y., Lamba, J., Schuetz, E., Lim, R., Lim, H.-L., Ong, A.-B., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.025 · Cited by 270
Klein, K., Lang, T., Saussele, T., Barbosa-Sicard, E., Schunck, W.-H., Eichelbaum, M., Schwab, M., & Zanger, U. M. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200512000-00004 · Cited by 269
Implications of CYP2A6 Genetic Variation for Smoking Behaviors and Nicotine Dependence*
Malaiyandi, V., Sellers, E. M., & Tyndale, R. F. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.10.011 · Cited by 267
Human CYP2B6: expression, inducibility and catalytic activities
Gervot, L., Rochat, B., Gautier, J. C., Bohnenstengel, F., Kroemer, H., de Berardinis, V., Martin, H., Beaune, P., & de Waziers, I. (1999) · Pharmacogenetics · doi:10.1097/00008571-199906000-00004 · Cited by 265
Huang, Z., Roy, P., & Waxman, D. J. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00410-4 · Cited by 263
Kaiser, R., Sezer, O., Papies, A., Bauer, S., Schelenz, C., Tremblay, P.-B., Possinger, K., Roots, I., & Brockmöller, J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.064 · Cited by 251
Cytochrome P 450 enzymes: Novel options for cancer therapeutics
McFadyen, M. C. E., Melvin, W. T., & Murray, G. I. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.363.3.3 · Cited by 243
Rasmussen (2002) · Pharmacogenetics · doi:10.1097/00008571-200208000-00008 · Cited by 241 · cited 1×
“…et al., 1999) and, interestingly, a study with twins phenotyped for CYP1A2 with caffeine activity showed that CYP1A2 activity was governed mainly by genetic factors, but also showed that induction by smoking is a powerful environmental factor that influences activity (Rasmussen et al., 2002).”
BackgroundCrewe, H. K., Notley, L. M., Wunsch, R. M., Lennard, M. S., & Gillam, E. M. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.8.869 · Cited by 241
Modification of Ocular Defects in Mouse Developmental Glaucoma Models by Tyrosinase
Libby, R. T., Smith, R. S., Savinova, O. V., Zabaleta, A., Martin, J. E., Gonzalez, F. J., & John, S. W. M. (2003) · Science · doi:10.1126/science.1080095 · Cited by 230
Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation
Xie, H.-J., Yasar, Ü., Lundgren, S., Griskevicius, L., Terelius, Y., Hassan, M., & Rane, A. (2003) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500157 · Cited by 215
Wang, H., Faucette, S., Sueyoshi, T., Moore, R., Ferguson, S., Negishi, M., & LeCluyse, E. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212482200 · Cited by 215
Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma
Löhr, M. J., Hoffmeyer, A., Kröger, J., Freund, M., Hain, J., Holle, A., Karle, P., Knöfel, W. T., Liebe, S., Müller, P., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04749-8 · Cited by 210
Oscarson, M., McLellan, R. A., Gullstén, H., Yue, Q., Lang, M. A., Bernal, M. L., Sinués, B., Hirvonen, A., Raunio, H., Pelkonen, O., et al. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00359-2 · Cited by 203
Self-citationCytochrome P 450 1B1 Is Overexpressed and Regulated by Hypomethylation in Prostate Cancer
Tokizane, T., Shiina, H., Igawa, M., Enokida, H., Urakami, S., Kawakami, T., Ogishima, T., Okino, S. T., Li, L.-C., Tanaka, Y., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2545 · Cited by 202
Human CYP1B1 and Anticancer Agent Metabolism: Mechanism for Tumor-Specific Drug Inactivation?
Rochat, B., Morsman, J. M., Murray, G. I., Figg, W. D., & McLeod, H. L. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38762-2 · Cited by 200
Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain
Miksys, S. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00136-9 · Cited by 199
Hesse, L. M., He, P., Krishnaswamy, S., Hao, Q., Hogan, K., Moltke, L. L., Greenblatt, D. J., & Court, M. H. (2004) · Pharmacogenetics · doi:10.1097/00008571-200404000-00002 · Cited by 193
Henningsson, A., Marsh, S., Loos, W. J., Karlsson, M. O., Garsa, A., Mross, K., Mielke, S., Viganò, L., Locatelli, A., Verweij, J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1152 · Cited by 188
Cytochrome P450 CYP1B1 protein expression:
McFadyen, M. C. E., McLeod, H. L., Jackson, F. C., Melvin, W. T., Doehmer, J., & Murray, G. I. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00643-8 · Cited by 188
Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide
Niemi, M. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00228-5 · Cited by 181
Aklillu, E., Carrillo, J. A., Makonnen, E., Hellman, K., Pitarque, M., Bertilsson, L., & Ingelman-Sundberg, M. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.3.659 · Cited by 181
Self-citationPozzi, A., Macias-Perez, I., Abair, T., Wei, S., Su, Y., Zent, R., Falck, J. R., & Capdevila, J. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501730200 · Cited by 178
Further Characterization of the Expression in Liver and Catalytic Activity of CYP2B6
Ekins, S., Vandenbranden, M., Ring, B. J., Gillespie, J. S., Yang, T. J., Gelboin, H. V., & Wrighton, S. A. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37719-5 · Cited by 178
Cytochrome P450 Profile of Colorectal Cancer: Identification of Markers of Prognosis
Kumarakulasingham, M., Rooney, P. H., Dundas, S. R., Telfer, C., Melvin, W. T., Curran, S., & Murray, G. I. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1848 · Cited by 171
Lee, S.-J., Usmani, K. A., Chanas, B., Ghanayem, B., Xi, T., Hodgson, E., Mohrenweiser, H. W., & Goldstein, J. A. (2003) · Pharmacogenetics · doi:10.1097/00008571-200308000-00004 · Cited by 167
Nakajima, M. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.112688 · Cited by 165
Gribben, J. G., Ryan, D. P., Boyajian, R., Urban, R. G., Hedley, M. L., Beach, K., Nealon, P., Matulonis, U., Campos, S., Gilligan, T. D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2111 · Cited by 165
Profiling Cytochrome P 450 Expression in Ovarian Cancer: Identification of Prognostic Markers
Downie, D., McFadyen, M. C. E., Rooney, P. H., Cruickshank, M. E., Parkin, D. E., Miller, I. D., Telfer, C., Melvin, W. T., & Murray, G. I. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0466 · Cited by 161
Cytochrome P450 Epoxygenase Metabolism of Arachidonic Acid Inhibits Apoptosis
Chen, J., Capdevila, J. H., & Harris, R. C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.18.6322-6331.2001 · Cited by 152
Landi, S., Gemignani, F., Moreno, V. R., Gioia‐Patricola, L., Chabrier, A., Guinó, E., Navarro, M., de, J., Capellá, G., & Canzian, F. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000165904.48994.3d · Cited by 150
Cytochrome P-450 1A1 Gene Polymorphisms and Risk of Breast Cancer: A HuGE Review
Masson, L. F., Sharp, L., Cotton, S. C., & Little, J. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi121 · Cited by 149
Spurdle, A. B., Goodwin, B. J., Hodgson, E., Hopper, J. L., Chen, X., Purdie, D. M., McCredie, M. R. E., Giles, G. G., Chenevix‐Trench, G., & Liddle, C. (2002) · Pharmacogenetics · doi:10.1097/00008571-200207000-00003 · Cited by 147
Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms
Yaşar, Ü., Lundgren, S., Eliasson, E., Bennet, A. M., Wiman, B., Fairé, U. D., & Rane, A. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02592-5 · Cited by 143
Ingelman‐Sundberg, M., & Rodríguez‐Antona, C. (2005) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2005.1685 · Cited by 134
Self-citationAklillu, E., Oscarson, M., Hidestrand, M., Leidvik, B., Otter, C. A., & Ingelman‐Sundberg, M. (2002) · Molecular Pharmacology · doi:10.1124/mol.61.3.586 · Cited by 133
Self-citationLang, T., Klein, K., Richter, T., Zibat, A., Kerb, R., Eichelbaum, M. F., Schwab, M. G., & Zanger, U. M. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068973 · Cited by 133
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel
Engels, F. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.01.001 · Cited by 130
Westlind-Johnsson, A., HERMANN, R., Huennemeyer, A., Hauns, B., Lahu, G., Nassr, N., Zech, K., Ingelman‐Sundberg, M., & von Richter, O. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.11.015 · Cited by 128
Self-citationButers, J. (2003) · Carcinogenesis · doi:10.1093/carcin/24.2.327 · Cited by 126
Daigo, S., Takahashi, Y., Fujieda, M., Ariyoshi, N., Yamazaki, H., Koizumi, W., Tanabe, S., Saigenji, K., Nagayama, S., Ikeda, K., et al. (2002) · Pharmacogenetics · doi:10.1097/00008571-200206000-00005 · Cited by 125
Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes
Mathijssen, R. H. J., de Jong, F. A., van Schaik, R. H. N., Lepper, E. R., Friberg, L. E., Rietveld, T., de Bruijn, P., Graveland, W. J., Figg, W. D., Verweij, J., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh298 · Cited by 124
McFadyen, M. C. E., Breeman, S., Payne, S., Stirk, C. M., Miller, I. D., Melvin, W. T., & Murray, G. I. (1999) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215549904701111 · Cited by 120
3′-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression
Wang, J., Pitarque, M., & Ingelman‐Sundberg, M. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.035 · Cited by 119
Self-citationRieger, M. A., Ebner, R., Bell, D., Kießling, A., Rohayem, J., Schmitz, M., Temme, A., Rieber, E. P., & Weigle, B. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0849 · Cited by 117
Leong, C.-O., Gaskell, M., Martin, E. A., Heydon, R. T., Farmer, P. B., Bibby, M. C., Cooper, P. A., Double, J. A., Bradshaw, T. D., & Stevens, M. F. G. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600719 · Cited by 114
From bench to bedside for gene-directed enzyme prodrug therapy of cancer
Dachs, G. U., Tupper, J., & Tozer, G. M. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200504000-00001 · Cited by 113
Rae, J. M., Soukhova, N. V., Flockhart, D. A., & Desta, Z. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.5.525 · Cited by 113
Novel extrahepatic cytochrome P450s
Karlgren, M., MIURA, S., & Ingelman‐Sundberg, M. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.12.022 · Cited by 112
Self-citationRodríguez‐Antona, C., Sayi, J., Gustafsson, L. L., Bertilsson, L., & Ingelman‐Sundberg, M. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.020 · Cited by 111
Self-citationSim, S. C., Edwards, R. J., Boobis, A. R., & Ingelman‐Sundberg, M. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000171516.84139.89 · Cited by 107
Self-citationKomatsu, T., Yamazaki, H., Shimada, N., Nakajima, M., & Yokoi, T. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)13674-4 · Cited by 105
Cytochrome P450 CYP3A4/5 Expression as a Biomarker of Outcome in Osteosarcoma
Dhaini, H. R., Thomas, D. G., Giordano, T. J., Johnson, T. D., Biermann, J. S., Leu, K. M., Hollenberg, P. F., & Baker, L. H. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.015 · Cited by 104
Quantitation of cytochrome P450 mRNA levels in human skin
Yengi, L. G., Xiang, Q., Pan, J., Scatina, J., Kao, J., Ball, S. E., Fruncillo, R. J., Ferron‐Brady, G., & Wolf, C. R. (2003) · Analytical Biochemistry · doi:10.1016/s0003-2697(03)00042-3 · Cited by 101
The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose
Dally, H., Edler, L., ger, B. J., Schmezer, P., Spiegelhalder, B., Dienemann, H., Drings, P., Schulz, V., Kayser, K., Bartsch, H., et al. (2003) · Pharmacogenetics · doi:10.1097/00008571-200310000-00004 · Cited by 100
Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues
Miyoshi, Y., Ando, A., Takamura, Y., Taguchi, T., Tamaki, Y., & Noguchi, S. (2001) · International Journal of Cancer · doi:10.1002/ijc.1568 · Cited by 100
Potential Role for Human Cytochrome P450 3A4 in Estradiol Homeostasis
Yu, A., Fukamachi, K., Krausz, K. W., Cheung, C., & Gonzalez, F. J. (2005) · Endocrinology · doi:10.1210/en.2004-1248 · Cited by 93
Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2
Han, X., Ouyang, D., Chen, X., Shu, Y., Jiang, C., Tan, Z., & Zhou, H. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01686.x · Cited by 92
Expression of cytochrome P450 in tumor tissues and its association with cancer development
Oyama, T. (2004) · Frontiers in bioscience · doi:10.2741/1378 · Cited by 89
CANCER CHEMOTHERAPY AND DRUG METABOLISM
Riddick, D. S., Lee, C., Ramji, S., Chinje, E. C., Cowen, R. L., Williams, K. J., Patterson, A. V., Stratford, I. J., Morrow, C. S., Townsend, A. J., et al. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004374 · Cited by 88
Yamamoto, N., Tamura, T., Murakami, H., Shimoyama, T., Nokihara, H., Ueda, Y., Sekine, I., Kunitoh, H., Ohe, Y., Kodama, T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.036 · Cited by 86
Tayeb, M. T., Clark, C., Haites, N. E., Sharp, L., Murray, G. I., & McLeod, H. L. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600825 · Cited by 78
Role of Gene Knockout and Transgenic Mice in the Study of Xenobiotic Metabolism
Gonzalez, F. J. (2003) · Drug Metabolism Reviews · doi:10.1081/dmr-120026496 · Cited by 57
Aklillu, E., Øvrebø, S., Botnen, I. V., Otter, C. A., & Ingelman‐Sundberg, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0113 · Cited by 55
Self-citationJacobson, P. A., Green, K., Birnbaum, A. K., et al. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0453-3 · Cited by 52
Miyoshi, Y., Taguchi, T., Kim, S. J., Tamaki, Y., & Noguchi, S. (2005) · Breast Cancer · doi:10.2325/jbcs.12.11 · Cited by 50
Conditional regulation of the human CYP4X1 and CYP4Z1 genes
Savas, Ü., Hsu, M., Griffin, K. J., et al. (2005) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2005.02.022 · Cited by 45
Gambier, N., Batt, A. G., Bastien, B., Pfister, M., Siest, G., & Visvikis‐Siest, S. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500314 · Cited by 40
Cited by
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
Ingelman-Sundberg, M., Sim, S. C., Gomez, A., & Rodriguez-Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,166
Self-citationNebert, D. W., & Dalton, T. P. (2006) · Nature Reviews Cancer · doi:10.1038/nrc2015 · Cited by 958
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
Alfarouk, K. O., Stock, C.-M., Taylor, S., Walsh, M., Muddathir, A. K., Verduzco, D., Bashir, A. H. H., Mohammed, O. Y., Elhassan, G. O., Harguindey, S., et al. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0221-1 · Cited by 665
Autophagy and multidrug resistance in cancer
Li, Y.-J., Lei, Y.-H., Yao, N., Wang, C.-R., Hu, N., Ye, W.-C., Zhang, D.-M., & Chen, Z.-S. (2017) · Chinese Journal of Cancer · doi:10.1186/s40880-017-0219-2 · Cited by 665
Metadata
- Authors
- Rodriguez-Antona, C., & Ingelman-Sundberg, M.
- Venue
- Oncogene
- Published
- 2006-03-13
- Volume
- 25
- Issue
- 11
- Pages
- 1679-1691
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2077522929
- Cited by
- 575
- References
- 98
- FWCI
- 25.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.